Chardan Capital Begins Coverage on Arcturus Therapeutics (ARCT)

Investment analysts at Chardan Capital initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report issued on Monday. The brokerage set a “buy” rating and a $12.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 31.15% from the stock’s current price.

Several other equities research analysts have also commented on ARCT. Roth Capital lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. WBB Securities upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Monday, October 9th. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Wednesday, October 4th. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Arcturus Therapeutics in a research report on Wednesday, November 29th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $3.08.

Shares of Arcturus Therapeutics (NASDAQ:ARCT) opened at $9.15 on Monday. The company has a market cap of $96.71, a price-to-earnings ratio of -2.29 and a beta of 1.55. Arcturus Therapeutics has a 1 year low of $6.51 and a 1 year high of $15.19.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.07). analysts forecast that Arcturus Therapeutics will post -0.81 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Chardan Capital Begins Coverage on Arcturus Therapeutics (ARCT)” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/22/chardan-capital-begins-coverage-on-arcturus-therapeutics-arct.html.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply